Defence Therapeutics Statistics
Total Valuation
DTCFF has a market cap or net worth of 32.78 million. The enterprise value is 32.28 million.
| Market Cap | 32.78M |
| Enterprise Value | 32.28M |
Important Dates
The last earnings date was Tuesday, May 27, 2025.
| Earnings Date | May 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 54.73M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +7.87% |
| Shares Change (QoQ) | +6.53% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 52.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -214.46 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.50 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -15.01 |
Financial Position
The company has a current ratio of 0.84
| Current Ratio | 0.84 |
| Quick Ratio | 0.84 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.45 |
| Interest Coverage | -10.04 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -169.45% |
| Return on Invested Capital (ROIC) | -1,183.48% |
| Return on Capital Employed (ROCE) | 2,055.62% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.51% in the last 52 weeks. The beta is 1.43, so DTCFF's price volatility has been higher than the market average.
| Beta (5Y) | 1.43 |
| 52-Week Price Change | -33.51% |
| 50-Day Moving Average | 0.62 |
| 200-Day Moving Average | 1.51 |
| Relative Strength Index (RSI) | 42.89 |
| Average Volume (20 Days) | 4,848 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.14M |
| Pretax Income | -2.58M |
| Net Income | -2.58M |
| EBITDA | -3.09M |
| EBIT | -3.14M |
| Earnings Per Share (EPS) | -0.05 |
Balance Sheet
The company has 1.45 million in cash and 968,820 in debt, giving a net cash position of 478,051.
| Cash & Cash Equivalents | 1.45M |
| Total Debt | 968,820 |
| Net Cash | 478,051 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -152,867 |
| Book Value Per Share | -0.00 |
| Working Capital | -286,355 |
Cash Flow
In the last 12 months, operating cash flow was -2.16 million and capital expenditures 11,787, giving a free cash flow of -2.15 million.
| Operating Cash Flow | -2.16M |
| Capital Expenditures | 11,787 |
| Free Cash Flow | -2.15M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DTCFF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.87% |
| Shareholder Yield | n/a |
| Earnings Yield | -7.88% |
| FCF Yield | -6.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |